Spots Global Cancer Trial Database for Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Official Title: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Study ID: NCT05891171
Study Description
Brief Summary: The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standard chemotherapy in participants with advanced malignancies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Lake City Cancer Care, LLC., Lake City, Florida, United States
Affinity Health-Hope and Healing Cancer Services, LLC, Hinsdale, Illinois, United States
Goshen Center for Cancer Care, Goshen, Indiana, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Gabrail Cancer Center, Canton, Ohio, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Next Oncology Dallas, Dallas, Texas, United States
Next Oncology Virginia, Fairfax, Virginia, United States
Queen Elizabeth Hospital, Adelaide, , Australia
Contact Details
Name: Medical Director
Affiliation: Arcus Biosciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
